Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

Research output: Contribution to journalJournal articleResearchpeer-review

  • Fabio Efficace
  • Francesco Cottone
  • Kathrin Sommer
  • Jacobien Kieffer
  • Neil Aaronson
  • Peter Fayers
  • Mogens Groenvold
  • Giovanni Caocci
  • Francesco Lo Coco
  • Gianluca Gaidano
  • Pasquale Niscola
  • Michele Baccarani
  • Gianantonio Rosti
  • Adriano Venditti
  • Emanuele Angelucci
  • Paola Fazi
  • Marco Vignetti
  • Johannes Giesinger
View graph of relations

OBJECTIVES: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with hematologic malignancies. Specifically, we evaluated the adequacy of a single-factor measurement model for the QLQ-C30, and its known-groups validity and responsiveness to change over time.

METHODS: We used confirmatory factor analysis to test the single-factor model of the QLQ-C30, using baseline QLQ-C30 data (N = 2134). The QLQ-C30 summary score was compared to the original QLQ-C30 scales using general (age, sex, Eastern Cooperative Oncology Group performance status, comorbidity) and disease-specific (red blood cell transfusion dependency) groups. Repeated measurements allowed us to investigate responsiveness to change in a subgroup of patients with acute myeloid leukemia.

RESULTS: The single-factor model of the QLQ-C30 exhibited adequate fit in patients with hematologic malignancies. Known-group comparisons generally supported the construct validity of the summary score when using more general grouping variables (sociodemographics, broad clinical parameters). Nevertheless, when groups were formed on the basis of disease-specific variables (eg, transfusion dependency), the summary score performed less well the some of the original, separate scales of the QLQ-C30.

CONCLUSION: Our findings provide support for the validity of the single-factor model of the EORTC QLQ-C30 in patients with hematologic malignancies. Specifically, the results suggest that the summary score can be used as an endpoint in this population when symptom- or other health domain-specific hypotheses are not available.

Original languageEnglish
JournalValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Volume22
Issue number11
Pages (from-to)1303-1310
Number of pages8
ISSN1098-3015
DOIs
Publication statusPublished - Nov 2019

ID: 58891009